<abstract xmlns="http://www.w3.org/1999/xhtml"><sec><h3>Introduction</h3><p>Intravitreal injections have become one of the most performed surgical procedures in ophthalmology. There is a need to look for an effective alternative therapy for patients with anti-VEGF complications and systemic disease contraindications.</p></sec><sec><h3>Aim of the study</h3><p>To evaluate Subliminal laser effectiveness on reducing macular disease edema.</p></sec><sec><h3>Materials and methods</h3><p>Subliminal laser treatment was done three times with three month intervals for patients with macular edema due to retinal diseases. On 1st, 3rd, 6th and 9th month visit the best corrected visual acuity, intraocular pressure, macular thickness and macular volume were registered.</p></sec><sec><h3>Results</h3><p>Mean visual acuity before treatment was 0,52 (SD=0,31) that changed to 0,56 after the 9 month treatment (p>0,05). Mean central macular thickness from 326,12 μm reduced to 308,15 (p=0,76). Without significant difference, inner cycle volume changed from 1353,80 mm3 to 1297,57 mm3 (p=0,81) and outer cycle volume from 1179,4 mm3 to 1112,56 mm3 (p=0,51).</p></sec><sec><h3>Conclusions</h3><p>Subliminal laser controls macular edema level and could be a solution for patients who cannot afford or are emotionally distressed by monthly intravitreal injections. This treatment method can be used as additional therapy to reduce the number of intravitreal injections.</p></sec></abstract>

IntroductionIntravitreal injections have become one of the most performed surgical procedures in ophthalmology. There is a need to look for an effective alternative therapy for patients with anti-VEGF complications and systemic disease contraindications.Aim of the studyTo evaluate Subliminal laser effectiveness on reducing macular disease edema.Materials and methodsSubliminal laser treatment was done three times with three month intervals for patients with macular edema due to retinal diseases. On 1st, 3rd, 6th and 9th month visit the best corrected visual acuity, intraocular pressure, macular thickness and macular volume were registered.ResultsMean visual acuity before treatment was 0,52 (SD=0,31) that changed to 0,56 after the 9 month treatment (p>0,05). Mean central macular thickness from 326,12 μm reduced to 308,15 (p=0,76). Without significant difference, inner cycle volume changed from 1353,80 mm3 to 1297,57 mm3 (p=0,81) and outer cycle volume from 1179,4 mm3 to 1112,56 mm3 (p=0,51).ConclusionsSubliminal laser controls macular edema level and could be a solution for patients who cannot afford or are emotionally distressed by monthly intravitreal injections. This treatment method can be used as additional therapy to reduce the number of intravitreal injections.

Subliminal Laser as Additional Therapy to Reduce Intravitreal Injection Number for the Patients with Macular Diseases

Pauls Stradins Clinical University Hospital

Acta Chirurgica Latviensis

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

IntroductionIntravitreal injections have become one of the most performed surgical procedures in ophthalmology. There is a need to look for an effective...

Subliminal Laser as Additional Therapy to Reduce Intravitreal Injection Number for the Patients with Macular Diseases

Publicado en línea: 18 nov 2020

Páginas: 45 - 47

DOI: https://doi.org/10.2478/chilat-2020-0011

Palabras clave
Subliminal laser, Macular disease, Intravitreal injections

© 2020 Liene Muceniece et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Subliminal Laser as Additional Therapy to Reduce Intravitreal Injection Number for the Patients with Macular Diseases

Publicado en línea: 18 nov 2020

Páginas: 45 - 47

DOI: https://doi.org/10.2478/chilat-2020-0011

Palabras claveSubliminal laser, Macular disease, Intravitreal injections

© 2020 Liene Muceniece et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Palabras clave
Subliminal laser, Macular disease, Intravitreal injections